Market-Moving News for June 20th
$ACN
$HROW
$TPST
Business Services
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 10/30/2024 | $375.00 | Outperform → Neutral | Exane BNP Paribas | |
| 9/30/2024 | $321.00 → $400.00 | Hold → Buy | TD Cowen | |
| 9/26/2024 | $329.00 → $395.00 | Neutral → Overweight | Piper Sandler | |
| 7/19/2024 | $400.00 | Neutral → Buy | UBS | |
| 6/26/2024 | $382.00 → $300.00 | Overweight → Equal-Weight | Morgan Stanley | |
| 6/24/2024 | $335.00 | Neutral | Goldman | |
| 5/15/2024 | $409.00 → $295.00 | Buy → Hold | Deutsche Bank | |
| 4/11/2024 | $24.00 | Buy | Craig Hallum |
10-Q - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
DEF 14A - Tempest Therapeutics, Inc. (0001544227) (Filer)
4 - Accenture plc (0001467373) (Issuer)
4 - Accenture plc (0001467373) (Issuer)
4 - Accenture plc (0001467373) (Issuer)
The Nasdaq 100 closed lower by more than 700 points during Wednesday's session. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga’s insider transactions platform. Bank of America The Trade: Bank of America Corporation (NYSE:BAC) President and CEO Jen Hsun Huang sold a
The Nasdaq 100 closed lower by around 0.4% during Tuesday's session. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga’s insider transactions platform. NVIDIA The Trade: NVIDIA Corporation (NASDAQ:NVDA) President and CEO Jen Hsun Huang sold a total of 240,000 shares a
Accenture (NYSE:ACN) has outperformed the market over the past 15 years by 3.91% on an annualized basis producing an average annual return of 16.18%. Currently, Accenture has a market capitalization of $207.81 billion. Buying $1000 In ACN: If an investor had bought $1000 of ACN stock 15 years ago, it would be worth $9,404.31 today based on a price of $331.76 for ACN at the time of writing. Accenture's Performance Over Last 15 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and r
Exane BNP Paribas downgraded Accenture from Outperform to Neutral and set a new price target of $375.00
TD Cowen upgraded Accenture from Hold to Buy and set a new price target of $400.00 from $321.00 previously
Piper Sandler upgraded Accenture from Neutral to Overweight and set a new price target of $395.00 from $329.00 previously
Accenture (NYSE:ACN) has invested, through Accenture Ventures, in Cresta, a company that has developed an AI-powered platform designed for contact centers. As part of this investment, Accenture plans to integrate Cresta's AI software capabilities into Accenture's AI Refinery™️ a comprehensive platform that helps clients to build custom AI models that meet their unique business needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241119090748/en/Accenture invests in Cresta (Photo: Business Wire) Generative AI is transforming customer experiences by creating seamless, personalized interactions that boost loyalty and operational e
Accenture (NYSE:ACN) has made a strategic investment, through Accenture Ventures, in Reality Defender, an RSA Innovation award-winning cybersecurity company specializing in deepfake detection. Together, Accenture and Reality Defender will equip clients in the financial services, media and high-tech industries with the ability to rapidly identify, detect, respond to and prevent deepfake fraud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241022558250/en/Accenture and Reality Defender to Help Organizations in Financial Services, Media and High-Tech Rapidly Identify, Detect, Respond to and Prevent Deepfake Fraud (Photo: Business W
BRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the appointment of Sheldon Mullins as Vice President, Regulatory Affairs. Mr. Mullins' presence on the team builds upon the recent addition of Troy Wagner as Vice President of Quality Assurance, who brought additional late-stage experience to the company. Additionally, in connection with the plan to advance amezalpat into a pivotal study in first-line HCC patients and to reflect their roles in late-stage development, the titles of Darrin Bomba and Henry John
Accenture (NYSE:ACN) has acquired Award Solutions, a provider of training and consulting services in advanced wireless and network technologies, including 5G, internet of things, and cloud-based solutions. Terms of the transaction were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241121330816/en/Accenture has acquired Award Solutions, a provider of training and consulting services in advanced wireless and network technologies, including 5G, internet of things, and cloud-based solutions. (Photo: Business Wire) Established in 1997, Award Solutions is headquartered in Plano, Texas, and has employees based in Las Cr
Jury in Trademark Infringement Case Finds in Favor of ImprimisRx Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced a favorable jury verdict in the case of ImprimisRx, LLC v. OSRX, Inc. ImprimisRx, a wholly owned subsidiary of Harrow, brought the lawsuit to a jury trial in a San Diego, California, federal court alleging willful acts of trademark infringement against OSRX, Inc. and its related party, Ocular Science, Inc. An eight-person jury in the United States District Court for the Southern District of California unanimously validated the entirety of ImprimisRx's subject trademark estate and found OSRX, Inc. or Ocular Science, Inc. acted with
MELT-300 Demonstrates Statistically Superior Compared to Both Sublingual Midazolam (P=0.009) and Placebo (P<0.001) for Providing Successful Procedural Sedation Proportion of Patients Requiring Rescue Sedation Was Nearly Two-Fold Higher for Sublingual Midazolam Compared with MELT-300 (P=0.003) MELT-300 Had a Favorable Safety Profile That Was Generally Comparable to Placebo Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced positive topline results of its pivotal Phase 3 study evaluating the safety and efficacy of its lead product candidate, MELT‑300, a non-IV, non-opioid tablet for procedural
4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)
SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)
Accenture (NYSE:ACN) has acquired Award Solutions, a provider of training and consulting services in advanced wireless and network technologies, including 5G, internet of things, and cloud-based solutions. Terms of the transaction were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241121330816/en/Accenture has acquired Award Solutions, a provider of training and consulting services in advanced wireless and network technologies, including 5G, internet of things, and cloud-based solutions. (Photo: Business Wire) Established in 1997, Award Solutions is headquartered in Plano, Texas, and has employees based in Las Cr
Third Quarter 2024 and Recent Selected Highlights: Revenues increased 44% from $34.3 million in the prior-year quarter to $49.3 million GAAP net loss of $(4.2) million Adjusted EBITDA of $8.8 million Operating cash flow of $3 million Cash and cash equivalents of $72.6 million as of September 30, 2024 VEVYE® total prescriptions up 55% over the second quarter of 2024 IHEEZO® customer unit demand volume up 15% over the second quarter of 2024 TRIESENCE® October 2024 relaunch underway Expansion of access and affordability through multiple new partnerships First major Medicare Part D win for VEVYE with major plan sponsors Fourth quarter revenue indicates meaningfu
Accenture (NYSE:ACN) has acquired Allitix, a consulting and technology company specializing in Anaplan solutions with capabilities across financial planning and analysis, sales performance management and supply chain. The acquisition further strengthens Accenture's connected planning capabilities using Anaplan, a platform that helps organizations see, plan and lead better business outcomes, and enhances its ability to help clients standardize planning practices across business functions for increased agility, productivity, and data-driven decision making. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241101706095/en/Accenture ha